PCK-HGFX7
Critical Limb Ischemia
Helixmith Co., Ltd.gene_therapyPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Critical Limb Ischemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Peripheral Blood Mononuclear Cell Mahidol University | Phase 3 | BB |
Pregabalin Karolinska Institutet | Phase 4 | BB |
TREPROSTINIL PHOSPHATE United Therapeutics | Phase 3 | B |
TREPROSTINIL DIETHANOLAMINE Southern Arizona Vascular Institute | Phase 2 | CCC |
Pvgi.1 | Phase 1 | CC |
Endothelial Progenitor Cells Allife Medical Science and Technology Co., Ltd. | Phase 1 | CC |
Same molecule, other indications
PCK-HGFX7 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →